Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer

NCT04425681 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Nanchang University as lead sponsor.

NCT NCT04425681
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04425681 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer
Lead sponsor
Second Affiliated Hospital of Nanchang University
Phase
Phase 2
Overall status
Unknown status
Start date
October 1, 2017
Completion date
June 1, 2021
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

egfr activating mutation, leptomeningeal metastasis, non-small cell lung cancer